Kelun-Biotech pulls in $349M share placing, top decile for China biotech

What's the deal? Kelun-Biotech has raised roughly $349 million through a placing of 5,838,000 new H shares, priced at HK$470.20 each. Goldman SachsDealroom has a profile for this one. Try Dealroom →, Citigroup, and J.P. Morgan acted as overall coordinators and placing agents.

The details: The Hong Kong-listed biopharmaceutical company (HK:6990) placed the shares with at least six independent investors under its general mandate, netting about HK$2,723.4 million. No new substantial shareholders emerged, leaving Kelun Pharmaceutical as the controlling shareholder.

What's the endgame? The company plans to channel most of the proceeds into research, clinical trials, regulatory filings, manufacturing, and commercialisation. Remaining funds will support internal R&D, external collaborations, pipeline expansion, and working capital.

Why it stands out: The round ranks in the top decile — the 91st percentile — of post-IPO equity raises in China's health sector over the trailing 48 months, across a sample of 64 comparable deals. That places Kelun-Biotech among the larger secondary raises in a competitive field.

The signal: The placing shows Chinese biotechs can still tap international capital at scale, with global banks underwriting the deal. For a sector chasing R&D-driven growth, access to that liquidity — and backing from analysts, who currently rate the stock a buy — remains a key edge.

Read more: TipRanks

Image credit: zhouxuan12345678